Nakazawa S, Satoh H, Niino K, Nakazawa S, Suzuki H, Iwasaki A, Chikaoka H, Oka S, Hirama Y, Narita A
Jpn J Antibiot. 1979 Nov;32(11):1081-90.
Cefamandole sodium (CMD) was intravenously administered and following laboratoric and clinical results were obtained. (1) The peak blood concentration was 32 approximately 44 micrograms/ml when the drip infusion was finished. At 1 hour after the end of the drip infusion the blood concentration was 7.6 approximately 8.1 micrograms/ml. Half life was approximately 0.64 hours. (2) Urinary recovery rate was 84.5 approximately 95% in active state within 6 hours. (3) Penetration of cerebrospinal fluid was found in 2 cases. (4) In most of 170 strains of Streptococcus haemolyticus MICs of cefamandole were 0.05 microgram/ml. They were less susceptible to cefazoline, cefmetazole and ceftezole. (5) CMD was administered to 35 pediatric patients (upper or lower RTI, lymphadenitis, enteritis or UTI) at 100 mg/kg/day for 3 approximately 9 days, the efficacy rate was 97.1%. (6) Side effect: Rash occurred in one case, and eosinophilia was observed in 4 cases. No abnormal finding of renal and liver function was observed.
静脉注射头孢孟多钠(CMD)后,得出以下实验室和临床结果:(1)静脉滴注结束时血药峰浓度约为32至44微克/毫升。滴注结束后1小时血药浓度为7.6至8.1微克/毫升。半衰期约为0.64小时。(2)6小时内活性状态下尿回收率为84.5%至95%。(3)发现2例脑脊液有渗透情况。(4)在170株溶血性链球菌中,大多数菌株对头孢孟多的最低抑菌浓度(MIC)为0.05微克/毫升。它们对头孢唑林、头孢美唑和头孢替唑较不敏感。(5)对35例儿科患者(上呼吸道或下呼吸道感染、淋巴结炎、肠炎或尿路感染)按100毫克/千克/天给予CMD,治疗3至9天,有效率为97.1%。(6)副作用:1例出现皮疹,4例观察到嗜酸性粒细胞增多。未观察到肝肾功能异常。